beta-alanine has been researched along with Glaucoma in 14 studies
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma." | 9.22 | Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022) |
| "Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy." | 6.66 | New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020) |
| " In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma." | 5.22 | Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022) |
| "Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy." | 2.66 | New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020) |
| "These cataracts were overall small, 1 to 3 mm, round, oval or ring-shaped, central or paracentral with mild density." | 1.72 | Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma. ( Chang, EL; Emmel, DK; Liu, J; Sarrafpour, S; Teng, CC, 2022) |
| "Presence of punctal stenosis after topical netarsudil use and resolution of punctal stenosis after cessation of therapy." | 1.72 | Punctal Stenosis Associated with Topical Netarsudil Use. ( Chen, PP; Meirick, TM; Mudumbai, RC; Zhang, MM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Shiuey, EJ | 1 |
| Mehran, NA | 2 |
| Ustaoglu, M | 1 |
| Zhang, Q | 1 |
| Razeghinejad, R | 3 |
| Shukla, AG | 1 |
| Kolomeyer, NN | 2 |
| Myers, JS | 2 |
| Lee, D | 2 |
| Chang, EL | 1 |
| Emmel, DK | 1 |
| Teng, CC | 1 |
| Sarrafpour, S | 1 |
| Liu, J | 1 |
| Meirick, TM | 1 |
| Mudumbai, RC | 1 |
| Zhang, MM | 1 |
| Chen, PP | 1 |
| Jeang, LJ | 1 |
| Shah, AS | 1 |
| Hammer, JD | 1 |
| Tuli, SS | 1 |
| Goergen, NS | 1 |
| Gagrani, M | 1 |
| Gulati, V | 1 |
| Ghate, D | 1 |
| Lee, JW | 1 |
| Ahn, HS | 1 |
| Chang, J | 1 |
| Kang, HY | 1 |
| Chang, DJ | 1 |
| Suh, JK | 1 |
| Lee, H | 1 |
| Bonardi, A | 1 |
| Supuran, CT | 1 |
| Sinha, S | 2 |
| Ostler, E | 1 |
| Rhee, D | 1 |
| Burney, E | 1 |
| Sozeri, Y | 1 |
| Mehta, AA | 1 |
| Kanu, LN | 1 |
| Sood-Mendiratta, S | 1 |
| Quinones, R | 1 |
| Hawkins, A | 1 |
| Lehrer, RA | 1 |
| Malhotra, K | 1 |
| Papas, R | 1 |
| Hillman, D | 1 |
| Wilensky, JT | 1 |
| Aref, AA | 1 |
| Vajaranant, TS | 1 |
| Edward, DP | 1 |
| Schehlein, EM | 1 |
| Robin, AL | 1 |
| Shaw, PX | 1 |
| Sang, A | 1 |
| Wang, Y | 1 |
| Ho, D | 1 |
| Douglas, C | 1 |
| Dia, L | 1 |
| Goldberg, JL | 1 |
5 reviews available for beta-alanine and Glaucoma
| Article | Year |
|---|---|
Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2022 |
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Combinations; Female; Glaucoma; Humans; Intra | 2020 |
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2020 |
Advances in medical therapy for glaucoma.
Topics: Administration, Ophthalmic; Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Humans; Intr | 2021 |
Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
Topics: Animals; Benzoates; beta-Alanine; Drug Therapy, Combination; Eye; Glaucoma; Humans; Intraocular Pres | 2019 |
9 other studies available for beta-alanine and Glaucoma
| Article | Year |
|---|---|
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.
Topics: Aged; Aged, 80 and over; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2022 |
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma.
Topics: Benzoates; beta-Alanine; Cataract; Glaucoma; Humans; Intraocular Pressure | 2022 |
Punctal Stenosis Associated with Topical Netarsudil Use.
Topics: Benzoates; beta-Alanine; Constriction, Pathologic; Eyelid Diseases; Glaucoma; Humans; Lacrimal Duct | 2022 |
Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.
Topics: Aged; Benzoates; beta-Alanine; Edema; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pr | 2022 |
Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma; Glaucom | 2022 |
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Topics: Benzoates; beta-Alanine; Glaucoma; Humans; Intraocular Pressure; Isoquinolines; Ocular Hypertension; | 2019 |
Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Cohort Studies; Glaucoma; Glaucoma, Open-Angle; Hu | 2022 |
Two new drugs for glaucoma.
Topics: Benzoates; beta-Alanine; Drug Approval; Glaucoma; Humans; Ophthalmic Solutions; Prostaglandins F, Sy | 2018 |
Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.
Topics: Administration, Topical; Animals; Axons; Benzoates; beta-Alanine; Blotting, Western; Cell Survival; | 2017 |